The Subcommittee on Consumer Protection and Commerce of the Committee on Energy and Commerce is set to examine the U.S. patent system this morning. Ahead of the hearing – and in honor of #ThrowBackThursay – we are resurfacing a piece by BIO’s Tom DiLenge that helps debunk some of the most…

The Trump Administration is moving forward with a plan to import foreign price controls into Medicare. Under the proposed International Pricing Index (IPI) model, the federal government would move away from a long-standing market-based reimbursement system to one that is tied to prices paid in…

BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest proposals being considered on Capitol Hill, the need to sustain biomedical innovation, and ways to ensure patients have access to the medicines they need with out-of-pocket costs they can afford…

BIO is out with a new whiteboard video that explores why more and more patients are facing higher costs when they go to the pharmacy to buy their prescription drugs. See how rebates and discounts within the drug cost ecosystem are often not used by insurers to lower patients’ out-of-pocket drug…

Experts recently gathered on Capitol Hill to discuss how importing foreign price controls will lead to less innovation and less patient access to breakthrough treatments. Leaders in biotech innovation, as well as within the patient community, have been sounding the alarm over a Trump-administration…

As the debate on drug pricing continues, our elected leaders will almost certainly adopt policies that will significantly impact—for better or for worse—the lives of many patients. With that in mind, how we do we ensure patients are at the center of this discussion? It starts by recognizing some…

In a rare show of bipartisan agreement, Congress recently passed and yesterday President Trump signed into law legislation that will ensure the country is ready and able to respond quickly to national health security threats. As an Ebola outbreak rages on in the Democratic Republic of Congo…

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property, recently testified at the second of three hearings in the Intellectual Property Subcommittee of the Senate Judiciary Committee on the subject of “The State of Patent Eligibility in America.” The hearings are looking at Section 101…

A new report from BIO and AUTM demonstrates to enormous return on investment that ultimately comes from public funding of early-stage basic research. The licensing of this research has significantly expanded US gross domestic product, industrial gross output, and jobs over the last 22 years.  …

Placing patients at the center of everything the biotech industry stands for is a personal mission for Christi Shaw. In 1996, her mother, Karen, died of breast cancer. It was a tragic time for her and her two sisters. But tragedy would strike again as Christi’s sister, Sherry, was later diagnosed…